Epione Biopharmaceuticals was formed to provide the benefits of highly efficacious, injectable medications for the treatment of pain in multiple markets without the burden and risks that opiate-based therapies offer. The worldwide incidence of acute and chronic pain, and the growing occurrence of mi…
Epione Biopharmaceuticals was formed to provide the benefits of highly efficacious, injectable medications for the treatment of pain in multiple markets without the burden and risks that opiate-based therapies offer. The worldwide incidence of acute and chronic pain, and the growing occurrence of migraine have lead to widespread consequences for both the healthcare system and the economy. First-line pain treatments are typically opiate-based medications; however, concerns regarding side effects, prescription drug abuse, risk of overdose, patient non-adherence to treatment regimens (accelerated dosing), and lack of efficacy in certain conditions provide challenges to providers, patients, regulators, and increasingly, law enforcement. Epione Biopharmaceuticals has developed a drug-device combination which includes Active Pharmaceutical Ingredients (APIs) which should be effective in clinical practice. Preliminary data on the efficacy of the medications and ease of delivery via sub-cutaneous or IM injection have been gathered, and demonstrate the medications provide opiate-level pain relief with no known risk of abuse or addiction.
Additionally, Epione has a pipeline that includes additional candidates in the pain space, the oncology space, as well as the orthopedic space.
Team (1)
Sectors Epione Biopharmaceuticals serves:
Life Sciences
Join Axial's Private M&A Platform
Epione Biopharmaceuticals connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
